Published online before print April 7, 2008, doi: 10.1161/HYPERTENSIONAHA.107.102152
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;51:1345.)
© 2008 American Heart Association, Inc.
Original Articles |
Involvement of Tumor Necrosis Factor-
in Angiotensin II–Mediated Effects on Salt Appetite, Hypertension, and Cardiac Hypertrophy
From the Comparative Biomedical Sciences (S.S., M.H., J.F.), School of Veterinary Medicine, Louisiana State University, Baton Rouge; the Department of Pharmacology (J.F.), Louisiana State University Health Sciences Center, New Orleans; and the Department of Physiology (D.S.A.M.), Tulane University Health Sciences Center, New Orleans, La.
Correspondence to Joseph Francis, Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, 1909 Skip Bertman Dr, Baton Rouge, LA 70803. E-mail jfrancis{at}lsu.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Hypertension is considered a low-grade inflammatory condition induced by various proinflammatory cytokines, including tumor necrosis factor (TNF)-
. Recent studies have implicated an involvement of TNF- in the development of salt-sensitive hypertension induced by angiotensin II (Ang II). To understand further the relationship between TNF- and Ang II, we examined the responses to Ang II in TNF- knockout (TNF-–/–) mice in the present study. A continuous infusion of Ang II (1 µg/kg per minute) for 2 weeks was given to both TNF-–/– and wild-type (WT) mice with implanted osmotic minipumps. Daily measurement of water intake, salt intake, and urine output were performed using metabolic cages. Blood pressure was monitored continuously with implanted radiotelemetry. Ang II administration for 2 weeks caused increases in salt (0.2±0.07 to 5.6±0.95 mL/d) and water (5.4±0.34 to 11.5±1.2 mL/d) intake and in mean arterial pressure (115±1 to 151±3 mm Hg) in wild-type mice, but these responses were absent in TNF-–/– mice (0.2±0.04 to 0.3±0.09 mL/d, 5.5±0.2 to 6.1±0.07 mL/d, and 113±2 to 123±3 mm Hg, respectively). Cardiac hypertrophy induced by Ang II was significantly attenuated in TNF-–/– mice compared with wild-type mice. In a group of TNF-–/– mice, when replacement therapy was made with recombinant TNF-, Ang II induced similar responses in salt appetite, mean arterial pressure, and cardiac hypertrophy, as observed in wild-type mice. These results suggest that TNF- plays a mechanistic role in mediating chronic Ang II–induced effects on salt appetite and blood pressure, as well as on cardiac hypertrophy.
Key Words: angiotensin II • TNF- • salt appetite • cardiac hypertrophy • hypertension
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Angiotensin (Ang) II, the effector peptide of the renin-angiotensin system (RAS), plays a key role in regulation of body fluid homeostasis, the development of hypertension, and the maintenance of cardiovascular function.1,2 Ang II is widely recognized for its vasoconstrictor effect, thereby regulating vascular tone and systemic blood pressure,3 and exerts its actions by binding to G protein–coupled receptors, angiotensin type 1 (AT1), and angiotensin type 2 (AT2), located on the plasma membrane of target cells throughout the body.4,5 The AT1 plays a predominant role in the central regulation of arterial blood pressure and cardiovascular remodeling.3,4
Ang II has been shown to have both central and peripheral effects. In the peripheral vasculature, it normally acts to raise arterial pressure by AT1–mediated vasoconstrictor effects. This pressor response of Ang II administration is also known to be partially modulated by the concomitant release of endothelin, prostaglandins, NO, superoxide, and other free radicals from endothelial cells.6 Ang II also contributes to cardiac and vascular remodeling through its direct effect on the heart and the blood vessels.2,7,8 In addition, Ang II stimulates aldosterone, which acts on the renal distal tubules and collecting ducts to retain sodium and water, thereby raising blood pressure.9 Centrally, Ang II plays an important role in regulating the salt appetite and thirst mediated by AT1.10–12 Apart from these, Ang II also acts as a growth factor and stimulator of proinflammatory cytokines, such as tumor necrosis factor (TNF)-, interleukin-6, and chemokines.13–15
TNF- is a multifunctional cytokine that plays an important role in diverse physiological and pathophysiological processes, such as inflammation, cell survival, growth, differentiation, and apoptosis.16,17 Because inflammation is a key component in the pathogenesis of hypertension and cardiovascular disease, the interaction between Ang II and TNF- may play an important role in the modulation of hypertensive response. Several in vitro and in vivo studies suggest the existence of cross-talk between the RAS and TNF-.13,18–20 For instance, Ang II treatment induces the production of TNF- in cultured cardiomyocytes and fibroblasts.13,21 In addition, TNF- treatment increased AT1 mRNA levels in neonatal rat cardiac fibroblasts.22 Administration of the AT1 receptor antagonist valsartan inhibited the expression of TNF- in a murine model of arterial injury.23 In patients with hypertension or heart failure, chronic blockade of AT1 resulted in a significant decrease in the circulating levels of TNF-.24,25 More importantly, blockade of TNF- by etanercept has been shown to prevent renal damage in genetically hypertensive rats and to lower blood pressure in rats with hypertension induced by Ang II and salt, suggesting a role for TNF- in blood pressure regulation and renal injury.26,27 A recent study showed that mice treated with etanercept prevented the hypertension and blunted the increase in superoxide production in response to Ang II.28 However, the functional importance of TNF- in Ang II–induced responses is not yet clearly defined. Therefore, in the present study, we examined the role of TNF- in the mediation of Ang II–induced responses, particularly its effects on salt appetite, thirst, and blood pressure, as well as its role in myocardial cell growth. The effects of chronic administration of Ang II have been evaluated in TNF- knockout mice and compared with those responses in wild-type (WT) control mice to dissect out the role played by TNF- in the Ang II–induced effects.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
An expanded Methods section can be found in the online data supplement, available at http://hyper.ahajournals.org.
Experimental Animals
Twelve-week-old male B6129S-Tnftm1Gkl/J TNF- knockout (TNF-–/–) mice and control B6129SF2/J (WT) mice (Jackson Laboratories, Bar Harbor, Maine) weighing between 25 and 30 g were used in this study. The mice were housed in a temperature-controlled room (23±2°C) with a 12:12 hour light-dark cycle from 7 AM to 7 PM in the animal quarters. The studies were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The experimental procedures were approved by the Louisiana State University Institutional Animal Care and Use Committee. They were randomly divided into different groups according to chronic treatment with or without Ang II. Osmotic minipumps were implanted SC to deliver Ang II (1 µg/kg per minute; Sigma Chemical) for 14 days. The control animals were implanted with sterile saline pumps. These groups are as follows: (1) WT (sham-operated control); (2) WT+Ang II (WT treated with chronic Ang II); (3) TNF-–/– (sham-operated control); (4) TNF-–/–+Ang II (knockout mice treated with chronic Ang II); and (5) TNF-–/–+Ang II+ TNF- (TNF-–replaced knockout mice treated with chronic Ang II). In this group of 6 TNF-–/– mice, along with Ang II infusion, human recombinant TNF- was given IP at a dose of 10 ng/g per day for 14 days. It should be noted here that we have not seen any sign of increasing susceptibility to infection in these TNF-–/– mice in preoperative or postoperative periods of surgical intervention for telemetry probes and minipump implantations.
Blood Pressure Measurements
In 1 set of experiments, mean arterial pressure in conscious mice was measured using a radiotelemetry system with carotid arterial catheters (Model TA11PA-C10, Data Sciences Intl). Mice were allowed to recover from the surgery for 7 to 10 days before experiments were begun. Data were collected, stored, and analyzed using Dataquest A.R.T. software (Data Sciences Intl).
Metabolic Cage Study
In another set of experiments, mice were individually housed in specially designed metabolic cages that prevented food and fecal contamination of urine samples. Food and water were available ad libitum. Mice were given both water and salt (1.8% sodium chloride) solution in 2 separate receptacles and were allowed to adapt to the metabolic cages for 7 days. After the acclimatization period, daily water intake, salt intake, and urine volume were measured at baseline and during the 14-day Ang II infusion period. At the end of 14 days, the mice were euthanized and the organs were weighed, and the hypothalamus and left ventricular tissues were collected for mRNA and protein measurements.
Echocardiography
Transthoracic echocardiography was performed on mice under isoflurane anesthesia using a Toshiba Aplio SSH770 (Toshiba Medical) fitted with a 12-MHz transducer at baseline, and after 14 days of Ang II infusion. Left ventricular internal dimensions at end systole and end diastole (LVS and LVD), and interventricular septal wall thickness at the end of systole and at the end of diastole were measured digitally on the M-mode tracings and averaged from 
3 cardiac cycles. Left ventricular fractional shortening was calculated as follows: [(LVD–LVS)/LVD]x100.
Protein Analysis by Western Blot
The protein expression in the heart and hypothalamus was analyzed by Western blot with the use of anti-AT1 antibody (Santa Cruz). Protein extracts (25 µg) were separated by electrophoresis on 10% SDS-polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Immobilon-P, Millipore) by electroblotting. Immunoreactive bands were visualized through the use of enhanced chemiluminescence and quantified by VersaDoc MP 5000 System (Bio-Rad).
Analysis of mRNA Expression by Real-Time PCR
Total RNA was isolated from left ventricular tissue and the hypothalamus using TRIzol reagent (Invitrogen) according to the manufacturer’s specifications. cDNA was synthesized from 1 µg of RNA with an iScript cDNA synthesis kit (Bio-Rad). Real-time PCR amplification reactions were performed with iQ SYBR Green Super mix with ROX (Bio-Rad) in triplicate using the ABI Prism 7900 real-time PCR machine (Applied Biosystems). Gene expression was measured by 
CT method and was normalized to 18S ribosomal RNA or GAPDH mRNA levels. The data are presented as the fold expressions of the gene of interest relative to their control animals.
Statistical Analysis
Data were analyzed by ANOVA, followed by Student t test. P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Blood Pressure Measurements
Continuous radiotelemetry recordings of arterial pressure showed that there were no significant differences in baseline blood pressure measurements among the groups (Figure 1). Ang II infusion for 14 days significantly increased mean arterial pressure in WT mice from 115±1 to 151±3 mm Hg (P<0.001) but not in TNF-
–/– mice (113±2 to 123±3 mm Hg). However, when TNF-–/– mice were given replacement therapy with human recombinant TNF-, Ang II administration caused an increase in mean arterial pressure (109±1 to 153±3 mm Hg; P<0.001), similar to that noted in WT mice.
|
Metabolic Parameters
At baseline, there were no significant differences in salt and water intakes and urine volumes between the WT and TNF-–/– groups. As illustrated in Figure 2, Ang II infusion for 14 days in WT mice caused significant increases in salt and water intake, as well as urine output, the increases of which were seen as early as day 5 of infusion. However, the salt and water intakes and urine output remained unchanged in the TNF-–/– mice infused with Ang II (Figure 2). Interestingly, the same treatment in the TNF-–/– mice receiving replacement therapy of human recombinant TNF- resulted in increases in salt intake, water intake, and urine output, noted especially in week 2 of the Ang II infusion.
|
Echocardiography
Echocardiography was performed to evaluate the effect of Ang II on left ventricular function in these WT and TNF-–/– mice (Table). The Ang II infusion significantly increased cardiac wall thickness and end-diastolic and end-systolic dimensions and decreased fractional shortening in WT mice. Conversely, in TNF-–/– mice, wall thickness, end-diastolic and end-systolic dimensions, or fractional shortening were not affected by Ang II infusion. These results indicated that cardiac function was well preserved in TNF-–/– mice.
|
Cardiac Hypertrophy Responses to Ang II Infusion
To evaluate changes in the cardiac weight in these Ang II–treated WT and TNF-–/– mice, the hearts were harvested and weighed at the end of the 2-week experimental period. The ratio of heart weight:body weight is calculated. Figure 3 illustrated these results on cardiac weight. There were no differences in vehicle-treated TNF-–/– and WT mice. In WT mice, Ang II infusion had increased heart weight and also increased the ratio between the heart weight and body weight. In contrast, the TNF-–/– mice with Ang II infusion did not show any increase in the heart weight:body weight ratio (Figure 3A). To further verify the attenuated hypertrophic response in TNF-–/– mice, mRNA levels of atrial natriuretic peptide in the left ventricle were measured by RT-PCR. Although the infusion of Ang II significantly increased myocardial levels of atrial natriuretic peptide in WT mice, this upregulation of atrial natriuretic peptide was significantly attenuated in TNF-–/– mice (Figure 3B).
|
Gene Expression Studies
To determine whether the infusion of Ang II alters the expression of AT1 receptors, we examined the mRNA levels of AT1 in the heart and hypothalamus by real-time PCR. AT1 mRNA expression was also assessed in the samples collected from WT (n=5 to 6) and TNF-–/– mice (n=5 to 6) before Ang II infusion. The basal level of AT1 mRNA expression was not significantly different between the groups. The AT1 mRNA expression in both heart and hypothalamus was significantly increased in Ang II–infused WT mice, whereas that in Ang II–infused TNF-–/– mice remained unchanged (Figure 4). These results were confirmed at protein levels by the Western blot analysis (Figure 5). Because both Ang II and TNF- have been shown to act through the nuclear factor 
B (NF-B)–mediated pathways, we analyzed the P50 subunit of NF-B mRNA expression using real-time PCR. Ang II infusion significantly increased the NF-B mRNA expression in WT mice but not in TNF-–/– mice (Figure 4C). To determine which TNF receptor is involved in Ang II infusion, the expression of TNF type 1 and type 2 in the left ventricle was analyzed. After Ang II infusion, there was a significant increase in TNF type 1 mRNA and protein expression in the WT but not in the TNF-–/– mice. However, there was no significant difference in the TNF type 2 mRNA expression (Figure S1).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study demonstrated that the responses to chronic Ang II administration on salt and water intake, blood pressure, and cardiac function were markedly attenuated in mice lacking the gene for the proinflammatory cytokine, TNF-
(TNF-–/– mice). However, these Ang II responses had been restored in TNF-–/– mice when these mice were given a replacement therapy with human recombinant TNF-. In addition, it was also observed that the mRNA levels of the AT1 receptor, as well as NF-B mRNA expressions in the heart and hypothalamus, were increased in response to chronic Ang II in WT but not in TNF-–/– mice. These results suggest that a concomitant generation of TNF- is involved in the complete expression of Ang II-induced salt appetite and hypertensive, as well as cardiac hypertrophic responses, possibly via the TNF-–induced upregulation of AT1 receptors, as well as activation of NF-B activity. Most of the known physiological actions of Ang II, such as vasoconstriction, increased aldosterone secretion, increased sympathetic nerve activity, and increased water and sodium intake, are mediated by the activation of AT1 receptors, which are widely distributed in all organs, including the liver, adrenal glands, brain, lung, kidney, heart, and blood vessels.4,29 AT1 receptors in the brain are linked to vasopressor responses, along with regulation of salt appetite, thirst, and modulation of vasopressin release.12,30,31 Salt appetite and thirst are central nervous system phenomenon. Injection of Ang II into the brain or into the periphery increases salt appetite and thirst in rodents.10,32,33 Ang II is a relatively large peptide, and it does not readily cross the blood-brain barrier. The central nervous system effect of the Ang II could be via the circumventricular organ, where the blood-brain barrier is weak or absent.12 These include the organum vasculosum lamina terminalis, subfornical organ, and area postrema. Ablation of the area postrema or organum vasculosum lamina terminalis regions attenuates the Ang II–induced response on salt appetite and thirst.12 Thus, all of the components of the RAS system are expressed within the central nervous system, thereby facilitating some of the Ang II–induced effect observed centrally.
Activation of the RAS and the subsequent increase in the local production of Ang II is one of the main mechanisms responsible for hypertension and the progression of cardiovascular disease. Ang II has been shown in many reports to increase the expression of various cytokines and chemokines that induce cardiac hypertrophy, inflammation, and vascular remodeling that result in the long-term regulation of blood pressure.2,3 Several studies have shown that blockade of the RAS by ANG-converting enzyme inhibitors or by AT1 receptor blockers attenuates hypertensive response and end organ damage, as well as inflammatory markers, in many cardiovascular diseases.34–36 It can be argued that the attenuated cardiac hypertrophy induced by Ang II in TNF-–/– mice could be the result of reduced blood pressure response in those animals and, thus, poses a potential limitation to data interpretation in the present study. Further studies are needed to examine the pressure-dependent and -independent components of the attenuated hypertrophic response in these TNF-–/– mice. However, accumulating evidence from clinical and experimental studies indicates that there is a functional crosstalk between Ang II and several proinflammatory cytokines, including TNF- and interleukin-6, in the regulation of cardiovascular function.13,18–20 Although there is considerable evidence from previous studies supporting a role for AT1 activation in Ang II–mediated hypertension, there have been very limited studies that examined the functional importance of TNF- in Ang II–induced hypertension and AT1 expression. The results from our present study demonstrated a more clear assessment of the functional involvement of the proinflammatory cytokine TNF- in the chronic Ang II–induced effects, particularly on salt appetite, blood pressure, and cardiac hypertrophy. However, it may be argued that the component of RAS may be altered, which may influence the responsiveness of Ang II in these TNF-–/– mice. However, this possibility may be unlikely, because we have observed that the basal tissue AT1 mRNA expression in both the heart and hypothalamus was not different between these TNF-–/– mice and WT mice. Further studies are required to define the various components of RAS in TNF-–/– mice.
It is well known that Ang II, by its direct effect on the activation of immune cells, induces the production of inflammatory mediators, such as TNF-, and contributes to tissue damage in hypertensive response.13–15 Recently, blockade of TNF- using etanercept has been shown to prevent renal damage in genetically hypertensive rats and to lower blood pressure in rats with hypertension induced by Ang II and salt, suggesting a role for TNF- in blood pressure regulation and renal injury.26,27 Thus, an interaction between Ang II and TNF- has been suggested to play an important role in hypertensive response.26,28,37 A recent study by Guzik et al28 showed that Ang II infusion caused infiltration of T lymphocytes in the aortic adventitia and periaortic fat, increased T-lymphocyte production of TNF-, increased vascular superoxide production, and led to hypertension in mice. Treatment with the TNF- antagonist etanercept prevented the hypertension and the increase in vascular superoxide caused by Ang II.28 Collectively, these data suggest the notion that chronic Ang II caused infiltration of T lymphocytes in various organ systems, including the cardiovascular and central nervous system, that facilitates the production of TNF-. This enhancement of TNF- production resulted in upregulation of AT1 receptors to further enhance the direct actions of Ang II in the target organs. In addition to these direct actions of Ang II, there are also effects of TNF-–mediated enhanced oxidative stress induced by activation of reduced nicotinamide-adenine dinucleotide phosphate oxidase, possibly via activation of NF-B activity.13,28
However, earlier studies had reported differing results regarding the role of TNF- in the regulation of blood pressure. It had been shown that TNF- opposed the vasoconstrictor effects of phenylephrine in rat aortic ring preparations.38 Ferreri et al37 demonstrated that the administration of anti–TNF- antiserum causes additional increases in mean arterial pressure in a model of Ang II–induced hypertension, indicating that TNF- may oppose the pressor actions of Ang II. However, a study by Alexander et al39 showed that infusion of TNF- at a dose of 50 ng/d for 5 days into virgin rats had no significant effect on blood pressure, but it produced a hypertensive response in pregnant animals. A recent study28 showed that mice treated with etanercept prevented the hypertension and blunted the increase in superoxide production in response to Ang II. These results also suggest that an interaction between TNF- and other factors, including oxidative stress, is required for full expression of this cytokine-induced hypertensive response.
Interaction between the RAS and TNF- in vivo in cardiac hypertrophy was apparent when losartan, an AT1 blocker, was given to transgenic mice overexpressing TNF- in the heart. Losartan prevented the development of hypertrophy, whereas vehicle treatment produced a significant increase in the heart weight:body weight ratio and LV wall thickness in transgenic mice overexpressing TNF-.40 Ang II has been shown to induce TNF- biosynthesis in the heart by activating NF-B, which, in turn, induces various proinflammatory cytokines and chemokines, including TNF-.13,41 Sustained application of TNF- induces an increase in AT1 mRNA levels in cardiac fibroblasts, which is dependent on NF-B activation.22,42 Ang II, on binding with its receptor, becomes internalized, resulting in the activation of its intracellular signaling mechanism. AT1 receptor–mediated cellular signaling events have been postulated to occur via the Gq mechanism. Interestingly, one of the downstream signaling mechanisms of Gq also involves NF-B activation. Similarly, TNF- production also involves NF-B translocation into the nucleus resulting in the perpetuation of TNF- and other proinflammatory cytokines. In support of the present finding, it has been shown that NF-B inhibition attenuates hypertensive response and end-organ damage in spontaneously hypertensive rats.43 Clearly, further studies are needed to understand the molecular mechanism involved in the TNF- and RAS interaction.
The present results may provide a beneficial therapeutic implication of the TNF- blocker in hypertensive patients who are also suffering from arthritis. At this moment, no direct clinical report is available that may indicate that treatment with a TNF- blocker may cause a decrease in blood pressure in arthritic patients or have any additive hypotensive effects with the blockers of RAS. Obviously, more comprehensive studies would be required to examine the therapeutic benefit of a TNF- blocker in the management of hypertension and/or arthritis in patients.
In conclusion, the results from the present study suggest that a concomitant generation of TNF- is required for the full expression of chronic Ang II–induced effects, such as salt appetite, hypertension, and cardiac hypertrophy, possibly via its action in upregulating AT1 receptors, as well as enhancing NF-B activity.
Perspectives
The findings of the present study emphasize an important mechanistic role of TNF- in the mediation of hypertensive and cardiac hypertrophy responses induced by chronic Ang II administration. These results demonstrate an existence of a crosstalk between the RAS and the proinflammatory cytokines in the regulation of cardiovascular and other organ functions. However, the specific mechanisms and the downstream signaling pathways by which these 2 systems interact with each other are not yet clearly defined. These present findings provide an important clue in our quest in understanding the pathophysiology of hypertension and other cardiovascular diseases. Thus, it is imperative that further emphasis should be focused on complete elucidation of the interactive role of the RAS and proinflammatory cytokines to increase our understanding of cardiovascular diseases that are linked with inflammatory process.
|
Acknowledgments |
|---|
Sources of Funding
These studies were supported by National Heart, Lung, and Blood Institute grant HL-80544 and Louisiana Board of Regents Louisiana Education Quality Support Fund grant to J.F. and by National Heart, Lung, and Blood Institute grant HL-66432 to D.S.A.M.
Disclosures
None.
Received October 2, 2007; first decision October 17, 2007; accepted March 6, 2008.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol. 2001; 87: 3C–9C.[Medline] [Order article via Infotrieve]
2. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension. 2001; 38: 1382–1387.
3. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000; 52: 11–34.
4. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J Hypertens. 2000; 13: 31S–38S.[CrossRef][Medline] [Order article via Infotrieve]
5. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991; 351: 233–236.[CrossRef][Medline] [Order article via Infotrieve]
6. Barton M, Shaw S, d’Uscio LV, Moreau P, Luscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun. 1997; 238: 861–865.[CrossRef][Medline] [Order article via Infotrieve]
7. Sadoshima J, Izumo S. Molecular characterization of angiotensin II–induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993; 73: 413–423.
8. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991; 17: 626–635.
9. Corvol P, Jeunemaitre X. Molecular genetics of human hypertension: role of angiotensinogen. Endocr Rev. 1997; 18: 662–677.
10. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest. 2000; 106: 103–106.[Medline] [Order article via Infotrieve]
11. Morris MJ, Wilson WL, Starbuck EM, Fitts DA. Forebrain circumventricular organs mediate salt appetite induced by intravenous angiotensin II in rats. Brain Res. 2002; 949: 42–50.[CrossRef][Medline] [Order article via Infotrieve]
12. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, Oldfield BJ, Mendelsohn FA, Chai SY. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol. 2003; 35: 901–918.[CrossRef][Medline] [Order article via Infotrieve]
13. Kalra D, Sivasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation. 2002; 105: 2198–2205.
14. Funakoshi Y, Ichiki T, Ito K, Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension. 1999; 34: 118–125.
15. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl. 2002: 12–22.
16. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002; 91: 988–998.
17. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications. Basic Res Cardiol. 2004; 99: 18–28.[CrossRef][Medline] [Order article via Infotrieve]
18. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol. 2004; 286: C779–C784.
19. Brasier AR, Li J, Wimbish KA. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension. 1996; 27: 1009–1017.
20. Sasamura H, Nakazato Y, Hayashida T, Kitamura Y, Hayashi M, Saruta T. Regulation of vascular type 1 angiotensin receptors by cytokines. Hypertension. 1997; 30: 35–41.
21. Yokoyama T, Sekiguchi K, Tanaka T, Tomaru K, Arai M, Suzuki T, Nagai R. Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts. Am J Physiol. 1999; 276: H1968–H1976.[Medline] [Order article via Infotrieve]
22. Gurantz D, Cowling RT, Villarreal FJ, Greenberg BH. Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors on cardiac fibroblasts. Circ Res. 1999; 85: 272–279.
23. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001; 104: 2716–2721.
24. Cottone S, Vadala A, Vella MC, Nardi E, Mule G, Contorno A, Riccobene R, Cerasola G. Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension. Am J Hypertens. 1998; 11: 548–553.[CrossRef][Medline] [Order article via Infotrieve]
25. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000; 35: 714–721.
26. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002; 161: 1679–1693.
27. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension. 2006; 47: 557–562.
28. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007; 204: 2449–2460.
29. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45: 205–251.[Medline] [Order article via Infotrieve]
30. Llorens-Cortes C, Mendelsohn FA. Organisation and functional role of the brain angiotensin system. J Renin Angiotensin Aldosterone Syst. 2002; 3 (suppl 1): S39–S48.
31. de Wardener HE. The hypothalamus and hypertension. Physiol Rev. 2001; 81: 1599–1658.
32. Wright JW, Sullivan MJ, Quirk WS, Batt CM, Harding JW. Heightened blood pressure and drinking responsiveness to intracerebroventricularly applied angiotensins in the spontaneously hypertensive rat. Brain Res. 1987; 420: 289–294.[CrossRef][Medline] [Order article via Infotrieve]
33. Denton DA, Blair-West JR, McBurnie M, Osborne PG, Tarjan E, Williams RM, Weisinger RS. Angiotensin and salt appetite of BALB/c mice. Am J Physiol. 1990; 259: R729–R735.[Medline] [Order article via Infotrieve]
34. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004; 110: 1456–1462.
35. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001; 104: 1615–1621.
36. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med. 2002; 113: 409–418.[CrossRef][Medline] [Order article via Infotrieve]
37. Ferreri NR, Zhao Y, Takizawa H, McGiff JC. Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens. 1997; 15: 1481–1484.[CrossRef][Medline] [Order article via Infotrieve]
38. Hollenberg SM, Cunnion RE, Parrillo JE. The effect of tumor necrosis factor on vascular smooth muscle. In vitro studies using rat aortic rings. Chest. 1991; 100: 1133–1137.[CrossRef][Medline] [Order article via Infotrieve]
39. Alexander BT, Cockrell KL, Massey MB, Bennett WA, Granger JP. Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens. 2002; 15: 170–175.[CrossRef][Medline] [Order article via Infotrieve]
40. Flesch M, Hoper A, Dell’Italia L, Evans K, Bond R, Peshock R, Diwan A, Brinsa TA, Wei CC, Sivasubramanian N, Spinale FG, Mann DL. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003; 108: 598–604.
41. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336: 1066–1071.
42. Cowling RT, Gurantz D, Peng J, Dillmann WH, Greenberg BH. Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta. J Biol Chem. 2002; 277: 5719–5724.
43. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005; 315: 51–57.
This article has been cited by other articles:
 |
|
 |
|
  Y.-M. Kang, Y. Ma, J.-P. Zheng, C. Elks, S. Sriramula, Z.-M. Yang, and J. Francis Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension Cardiovasc Res, June 1, 2009; 82(3): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Itani, X. Liu, E. H. Sarsour, P. C. Goswami, E. Born, H. L. Keen, and C. D. Sigmund Regulation of Renin Gene Expression by Oxidative Stress Hypertension, June 1, 2009; 53(6): 1070 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Elks, N. Mariappan, M. Haque, A. Guggilam, D. S. A. Majid, and J. Francis Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR Am J Physiol Renal Physiol, February 1, 2009; 296(2): F298 - F305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shahid, J. Francis, and D. S. A. Majid Tumor necrosis factor-{alpha} induces renal vasoconstriction as well as natriuresis in mice Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1836 - F1844. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||